LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
To help evaluate your risk of developing cardiovascular disease (CVD); sometimes to help monitor treatment for high cholesterol or to help diagnose a rare inherited apolipoprotein B (apo B) deficiency
When you have a personal or family history of heart disease and/or high cholesterol and triglyceride levels and your healthcare provider is trying to determine your risk of developing CVD; sometimes on a regular basis when you are being treated for high cholesterol; rarely when your healthcare practitioner suspects that you have an inherited apo B deficiency
A blood sample drawn from a vein in your arm
No special preparation is needed for an apo B test. However, since this test is often ordered at the same time as other tests that do require fasting, such as LDL-C, HDL-C and triglycerides, fasting for at least 12 hours may be required.
Apolipoprotein B-100 (also called apolipoprotein B or apo B) is a protein that is involved in the metabolism of lipids and is the main protein constituent of lipoproteins such as very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL, the "bad cholesterol"). This test measures the amount of apo B in the blood.
Apolipoproteins combine with lipids to transport them throughout the bloodstream. Apolipoproteins provide structural integrity to lipoproteins and shield the water-repellent (hydrophobic) lipids at their center. Most lipoproteins are cholesterol- or triglyceride-rich and carry lipids through the body for uptake by cells.
Chylomicrons are the lipoprotein particles that carry dietary lipids from the digestive tract, via the bloodstream, to tissue – mainly the liver. In the liver, the body repackages these dietary lipids and combines them with apo B-100 to form triglyceride-rich VLDL. This combination is like a taxi full of passengers with apo B-100 as the taxi driver. In the bloodstream, the taxi moves from place to place, releasing one passenger at a time.
An enzyme called lipoprotein lipase (LPL) removes triglycerides from VLDL to produce intermediate density lipoproteins (IDL) first and then LDL. Each VLDL particle contains one molecule of apo B-100, which is retained as VLDL loses triglycerides and shrinks to become the more cholesterol-rich LDL. Apo B-100 is recognized by receptors found on the surface of many of the body's cells. These receptors promote the uptake of cholesterol into the cells.
The cholesterol that LDL and apo B-100 transport is vital for cell membrane integrity, sex hormone production, and steroid production. In excess, however, LDL can lead to fatty deposits (plaques) in artery walls and lead to hardening and scarring of the blood vessels. These fatty depositions narrow the vessels in a process termed atherosclerosis. The atherosclerotic process increases the risk of heart attack.
Apo B-100 levels tend to mirror LDL-C levels, a test routinely ordered as part of a lipid profile. Many experts think that apo B levels may eventually prove to be a better indicator of risk of cardiovascular disease (CVD) than LDL-C. Some recommend the measurement of apo B to help with risk prediction when a person has multiple risk factors. Other experts disagree; they feel that apo B is only a marginally better alternative and do not recommend its routine use. The clinical utility of apo B and that of other emerging cardiac risk markers such as apo A-I, Lp(a), and hs-CRP has yet to be fully established.
The apolipoprotein B (apo B) test is used, along with other lipid tests, to help determine an individual's risk of developing cardiovascular disease (CVD).
This test is not used as a general population screen but may be ordered if a person has a family history of heart disease and/or high cholesterol and triglycerides (hyperlipidemia). It may be performed, along with other tests, to help diagnose the cause of abnormal lipid levels, especially when someone has elevated triglyceride levels.
A healthcare practitioner may order both an apo A-I (associated with high-density lipoprotein (HDL), the "good" cholesterol) and an apo B to determine an apo B/apo A-I ratio. This ratio is sometimes used as an alternative to a total cholesterol/HDL ratio to evaluate risk for developing CVD.
In rare cases, an apo B test may be ordered to help diagnose a genetic problem that causes over- or under-production of apo B.
Apo B may be measured, along with an apo A-I or other lipid tests, when a healthcare practitioner is trying to evaluate someone's risk of developing CVD and when a person has a personal or family history of heart disease and/or abnormal lipid levels, especially when the person has significantly elevated triglyceride levels.
Sometimes apo B is ordered to monitor a person who is undergoing treatment for high cholesterol.
Elevated levels of apo B correspond to elevated levels of LDL-C and to non-HDL-C and are associated with an increased risk of cardiovascular disease (CVD). Elevations may be due to a high-fat diet and/or decreased clearing of LDL from the blood.
Some genetic disorders are the direct (primary) cause of abnormal levels of apo B. For example, familial combined hyperlipidemia is an inherited disorder causing high blood levels of cholesterol and triglycerides. Abetalipoproteinemia, also called Apolipoprotein B deficiency or Bassen-Kornzweig syndrome, is a very rare genetic condition that can cause abnormally low levels of apo B. For more on some of these disorders, see the Related Content section.
Abnormal levels of apo B can also be caused by underlying conditions or other factors (secondary causes). Increased levels of apo B are seen, for example, in:
Apo B levels may be decreased with any condition that affects lipoprotein production or affects its synthesis and packaging in the liver. Lower levels are seen with secondary causes such as:
An increased ratio of apo B to apo A-I may indicate a higher risk of developing CVD.
Chylomicrons, the lipoprotein particles that carry dietary lipids to the liver, contain a lipoprotein called apolipoprotein B-48. It is about half the size of apo B-100 and is structurally related to apo B-100. It is not considered a risk factor for atherosclerosis and is not measured as part of the apo-B test. The apo B test is specific for apo B-100.
Some elevations of apo B-100 (and LDL-C) are due to mutations in the APOB gene that cause it to produce apo B-100 that is not recognized as easily by LDL receptors. Others are in the LDL receptor system of the liver cell that recognizes apo B-100. These genetic defects impede the clearing of LDL from the blood and result in accumulations of LDL in the circulation, increasing the risk of heart disease.
No, the apo B test requires specialized equipment and is not offered by every laboratory. Your blood may need to be sent to a reference laboratory for testing.
Sources Used in Current Review
Meeusen, J. (2018 May). Apolipoprotein B or Low-Density Lipoprotein Cholesterol: Is It Time for a Twenty-First-Century Lipid Marker? Clin Chem 2018 64 (6), p. 984. Available online at http://clinchem.aaccjnls.org/content/64/6/984. Accessed on 9/08/18.
Rosenso, R. et. al. (2016 January 19). Integrated Measure for Atherogenic Lipoproteins in the Modern Era: Risk Assessment Based on Apolipoprotein B. JACC v67(2). 202-204. Available online at https://www.sciencedirect.com/science/article/pii/S0735109715072587?via%3Dihub. Accessed on 9/08/18.
Delgado, J. et. al. (2018 August, Updated). Atherosclerotic Cardiovascular Disease (ASCVD) Nontraditional Risk Markers - Cardiovascular Disease Risk Markers (Nontraditional). ARUP Consult. Available online at https://arupconsult.com/content/cardiovascular-disease-non-traditional-risk-markers. Accessed on 9/08/18.
(© 1995– 2018). Apolipoprotein B, Plasma. Mayo Clinic Mayo Medical Laboratories. Available online at https://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/80308. Accessed on 9/08/18.
Morita, S. (2016). Metabolism and Modification of Apolipoprotein B-Containing Lipoproteins Involved in Dyslipidemia and Atherosclerosis. Biol Pharm Bull 39, 1-24 (2016). Available online at https://www.jstage.jst.go.jp/article/bpb/39/1/39_b15-00716/_article. Accessed on 9/08/18.
Szternel, L. et. al. (2018 June 21). Non-fasting lipid profile determination in presumably healthy children: Impact on the assessment of lipid abnormalities. PLoS One. 2018 Jun 21;13(6):e0198433. Available online at https://www.ncbi.nlm.nih.gov/pubmed/29927973. Accessed on 9/08/18.
Kim, S. et. al. (2017 September 28). The association between the apolipoprotein B/A-I ratio and coronary calcification may differ depending on kidney function in a healthy population. PLoS One. 2017 Sep 28;12(9):e0185522. Available online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619778/. Accessed on 9/08/18.
Sources Used in Previous Reviews
Thomas, Clayton L., Editor (1997). Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].
Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby's Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.
Apolipoprotein B Mutation Detection. ARUP's Guide to Clinical Laboratory Testing (CLT) [On-line information]. Available online at http://www.arup-lab.com/guides/clt/tests/clt_al68.htm#1872677.
Angelo, S., Reviewed (2001 November 21, Reviewed). Apolipoprotein B100. University of Pennsylvania Health System Encyclopedia [On-line information]. Available online at http://www.pennhealth.com/ency/article/003502.htm.
Gianturco, S. & Bradley, W. (1999). Pathophysiology of Triglyceride-Rich Lipoproteins in Atherothrombosis: Cellular Aspects. Clin. Cardiol. 22, (Suppl. 11) 11-7-11-14 [On-line Journal]. PDF available for download at http://www.clinicalcardiology.org/supplements/CC22S2/CC22S207.pdf.
Blanchear, M. (2000 April 22). Lipoprotein Interconversions. University of Manitoba, Tutorials in Biochemistry [On-line information]. Available online through http://www.umanitoba.ca.
(2001 October). Apolipoprotein B, Detecting Familial Hypercholesterolemia. ARUP [On-line Technical Bulletin]. Available online at http://www.aruplab.com/testbltn/apolipopro.htm.
(2002 October 25, Updated). Apolipoprotein B100. MedlinePlus Health Information [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/003502.htm.
(2001 October 30). Bassen-Kornzweig Syndrome. MedlinePlus Health Information [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/001666.htm.
Pagana, Kathleen D. & Pagana, Timothy J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO., Pp 110-114.
Clarke, W. and Dufour, D. R., Editors (2006). Contemporary Practice in Clinical Chemistry, AACC Press, Washington, DC. Winter, W. and Harris, N. Chapter 21: Lipoprotein Disorders, Pp 251-259.
(2006 August). Abetalipoproteinemia. Genetics Home Reference [On-line information]. Accessed on: 4/29/07 Available online at http://ghr.nlm.nih.gov/condition=abetalipoproteinemia.
Gandelman, G. (2007 February 7, Updated). Apolipoprotein B100. MedlinePlus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/003502.htm. Accessed on 4/29/07
Sondheimer, N. (2005 April 20, Updated). Bassen-Kornzweig syndrome. MedlinePlus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/001666.htm. Accessed on 4/29/07
Kasper D, et al, eds. (2005). Harrision's Principles of Internal Medicine 16th edition, McGraw Hill.
Zieve, D. and Dugdale, D. (Updated 2010 May 23). Apolipoprotein B100. MedlinePlus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/003502.htm. Accessed July 2010.
Ganda, O. (2009 August 31). Refining Lipoprotein Assessment in Diabetes: Apolipoprotein B Makes Sense. Medscape from Endocrine Practice. 2009;15(4):370-376 [On-line information]. Available online at http://www.medscape.com/viewarticle/707433. Accessed July 2010.
Benderly, M. et. al. (2009 February 16). Apolipoproteins and Long-Term Prognosis in Coronary Heart Disease Patients. Medscape from American Heart Journal. 2009;157(1):103-110 [On-line information]. Available online at http://www.medscape.com/viewarticle/585982. Accessed July 2010.
Delgado, J. et. al. (Updated 2010 April). Cardiovascular Disease (Non-traditional Risk Markers) - Risk Markers - CVD (Non-traditional). ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/CVDRiskMarkerNontrad.html?client_ID=LTD# . Accessed July 2010.
(© 1995–2010). Unit Code 80308: Apolipoprotein B, Plasma. Mayo Clinic, Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/80308. Accessed July 2010.
Myers, G. Editor (2009). Emerging Biomarkers for Primary Prevention of Cardiovascular Disease and Stroke. The National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines [On-line information]. PDF available for download at http://www.aacc.org/members/nacb/LMPG/OnlineGuide/PublishedGuidelines/risk/Documents/EmergingCV_RiskFactors09.pdf. Accessed July 2010.
Pagana, K. D. & Pagana, T. J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 110-114.
Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 146-149.
Contois J, et al. Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 55(3):407 (2009). Available online at http://www.clinchem.org/cgi/reprint/55/3/407. Accessed Sept 2010.
Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Burtis CA, Ashwood ER, Bruns DE, eds. St. Louis: Elsevier Saunders; 2006 Pp 916-917, 928-934.
Zieve, D. (Updated 2012 June 4). Apolipoprotein B100. MedlinePlus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/003502.htm. Accessed March 2014.
Zieve, D. (Updated 2012 June 4). Familial combined hyperlipidemia. MedlinePlus Medical Encyclopedia [On-line information]. Available online at [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/000396.htm. Accessed March 2014.
(© 1995–2014). Apolipoprotein B, Plasma. Mayo Clinic Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/80308. Accessed March 2014.
Delgado, J. et. al. (Updated 2014 February). Cardiovascular Disease (Non-traditional Risk Markers) - Risk Markers - CVD (Non-traditional) ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/CVDRiskMarkerNontrad.html?client_ID=LTD. Accessed March 2014.
Ford, E. et. al. (2013). Temporal Changes in Concentrations of Lipids and Apolipoprotein B Among Adults With Diagnosed and Undiagnosed Diabetes, Prediabetes, and Normoglycemia Findings From the National Health and Nutrition Examination Survey 1988-1991 to 2005-2008. Medscape Multispecialty from Cardiovasc Diabetol. 2013;12(26) [On-line information]. Available online at http://www.medscape.com/viewarticle/781844. Accessed March 2014.
Elhomsy, G and Griffing, G. (Updated 2012 July 10). Apolipoprotein B. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/2087335-overview. Accessed March 2014.